Nuvectis Pharma, Inc. — Director's Dealing 2022

Feb 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2022-02-04

Reporting Person: Shemesh Shay (Chief Development Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-04	Common Stock, par value $0.00001	P	2100	$3.38	Acquired	1178769	Direct
2022-02-07	Common Stock, par value $0.00001	P	846	$3.47	Acquired	1179615	Direct

Footnotes

F1: Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.31 to $3.44. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: Includes 48,399 shares of restricted stock.

F3: Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.43 to $3.49. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

F4: Includes 48,399 shares of restricted stock.